GLP-1s, Strategy, and the Future of Obesity Medicine: with Dr. Kristin Baier
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
GLP-1s, Strategy, and the Future of Obesity Medicine: with Dr. Kristin Baier
-
ナレーター：
-
著者：
このコンテンツについて
Dr. Kristin Baier is the Chief Medical Officer at Vineyard and a board-certified expert in both Obesity and Family Medicine. With over 20 years in healthcare, Kristin has built a reputation at the intersection of medicine, tech, and strategy—leading clinical teams and scaling solutions at some of the most recognized names in healthtech, including Calibrate, Teladoc, and now Vineyard.
She’s pioneered the integration of GLP-1s and metabolic health programming, led clinical transitions from DTC to B2B, and trained hundreds of providers on evidence-based anti-obesity treatment. On top of that, she’s currently pursuing an MBA in Healthcare Administration, showing her continued commitment to leading from both the clinic and the boardroom.
In this conversation, we dive into the evolution of obesity medicine, what it takes to scale clinical innovation, and the real story behind building sustainable models for patient outcomes at scale.
Where executives discuss strategic marketing to spark growth and profitability